Gastrointestinal Bleeding Rajeev Jain, M.D.. GI Bleeding Clinical Presentation Acute Upper GI Bleed...

download Gastrointestinal Bleeding Rajeev Jain, M.D.. GI Bleeding Clinical Presentation Acute Upper GI Bleed Acute Lower GI Bleed

of 51

  • date post

    31-Mar-2015
  • Category

    Documents

  • view

    222
  • download

    3

Embed Size (px)

Transcript of Gastrointestinal Bleeding Rajeev Jain, M.D.. GI Bleeding Clinical Presentation Acute Upper GI Bleed...

  • Slide 1

Gastrointestinal Bleeding Rajeev Jain, M.D. Slide 2 GI Bleeding Clinical Presentation Acute Upper GI Bleed Acute Lower GI Bleed Slide 3 Core Principles in GI Bleeding Management Assessment and stabilization of hemodynamic status Determine the source of bleeding Stop active bleeding Treatment of underlying abnormality Prevent recurrent bleeding Slide 4 GI Bleeding Management Definitions Hematemesis: bloody vomitus (bright red or coffee-grounds) Melena: black, tarry, foul-smelling stool Hematochezia: bright red or maroon blood per rectum Occult: positive stool occult test Symptoms of anemia: angina, dyspnea, or lightheadedness Slide 5 GI Bleeding Management Patient Assessment Hemodynamic status Localization of bleeding source CBC, PT, and T & C Risk factors Prior h/o PUD or bleeding Cirrhosis Coagulopathy ASA or NSAIDs Slide 6 GI Bleeding Management Initial Patient Assessment Vital SignsBlood Loss Severity of GI Bleed Shock (resting hypotension) 20-25%Massive Postural (orthostatic hypotension) 10-20%Moderate Normal UGIB Risk Stratification AIMS65 Albumin < 3.0 g/dL, INR > 1.5, Altered mental status, Systolic blood pressure 90 mm Hg or lower, and Age older > 65 years. Saltzman JR et al. Gastrointest Endosc 2011:1215-22. Large clinical database - CareFusion 187 US hospitals Recursive partitioning 2004-5 29,222 pts to derive risk score 2006-7 32,504 pts to validate Slide 13 UGIB Risk Stratification AIMS65 Saltzman JR et al. Gastrointest Endosc 2011:1215-22. Slide 14 Peptic ulcer disease Gastric ulcer Duodenal ulcer Mallory-Weiss tear Varices Esophagitis Dieulafoys lesion Vascular anomalies Malignancy Post-procedural Camerons lesions Hemobilia Hemorrhagic gastropathy Aortoenteric fistula Acute UGIB Differential Diagnosis Major CausesMinor Causes Slide 15 Peptic Ulcer Disease Forrest ClassStigmata IAArterial spurting IBArterial oozing IIAVisible vessel IIBAdherent clot IICPigmented flat spot IIIClean based Forrest JA, Finlayson ND, Shearman DJ: Endoscopy in gastrointestinal bleeding. Lancet 1974; 2:394-7Endoscopy in gastrointestinal bleeding. Slide 16 Endoscopic Appearance of Ulcers Clean based ulcerNonbleeding visible vessel Slide 17 Risk Stratification after Endoscopy Slide 18 Prognostic Features at Endoscopy in Acute Ulcer Bleeding Slide 19 Thermal Bipolar probe Monopolar probe Argon plasma coagulator Heater probe Mechanical Hemoclips Band ligation Injection Epinephrine Alcohol Ethanolamine Polidocal Endoscopic Therapy of PUD Slide 20 Laine and Peterson New Eng J Med 1994;331:717-27. Slide 21 Risk of Recurrent Bleeding after Endoscopic Therapy Slide 22 Effect of Proton-Pump Inhibition on Peptic Ulcer Bleeding Gralnek et al. New Eng J Med 2008;359:928-37. Slide 23 Management of PUD after EGD in High Risk Pts Proton-pump inhibitor 80 mg IV bolus dose plus continuous infusion for 72 hrs Admit to monitored bed or ICU setting Initiate oral intake of clear liquid diet 6 hrs after EGD in pts with hemodynamic stability Transition to oral PPI after completing IV course Perform testing for H. pylori infection For selected patients, discuss need for NSAIDs and antiplatelet therapy Gralnek et al. New Eng J Med 2008;359:928-37. Slide 24 Management of PUD after EGD in Low Risk Pts Oral proton-pump inhibitor Initiate oral intake with a regular diet 6 hrs after EGD in pts with hemodynamic stability Perform testing for H. pylori infection For selected patients, discuss need for NSAIDs and antiplatelet therapy Consider early discharge in selected pts Gralnek et al. New Eng J Med 2008;359:928-37. Slide 25 Mallory-Weiss Tear Slide 26 Esophageal Varices Slide 27 Management of Acute Variceal Bleeding Suspected Variceal Bleeding Endoscopy Band ligation or sclerotherapy Continue Octreotide for 5 days Early rebleeding Failure to control TIPS or surgery Octreotide 50 ug bolus, 50 ug/hr Conservative blood volume resuscitation Antibiotics Slide 28 Antibiotic Prophylaxis in GI Bleeding in Cirrhotic Patients Fluoroquinolones or amoxicillin + clavulinic acid Meta-analysis 1 Decrease rates of infection SBP, bacteremia Increased short-term survival RCT 2 Reduction in early rebleeding 1.Bernard et al.Hepatology. 29(6):1655-61.1999. 2.Hou et al. Hepatology. 39(3):746-53.2004. Slide 29 Variceal Band Ligation Slide 30 Transjugular Intrahepatic Portosystemic Shunt (TIPS) IVC Portal Vein Splenic Vein Coronary Vein Slide 31 Aortoduodenal Fistula Aorta Duodenum Graft Fistula Slide 32 Acute UGIB Surgery Recurrent bleeding despite endoscopic therapy > 6-8 units pRBCs Slide 33 Management of Ulcer Bleeding: ACG Guidelines Initial Assessment and Risk Stratification Hemodynamic status should be assessed immediately upon presentation and resuscitative measures begun as needed (Strong recommendation). Blood transfusions should target Hgb 7 g / dl, with higher Hgbs targeted in patients with clinical evidence of intravascular volume depletion or comorbidities, such as coronary artery disease (Conditional recommendation). Risk assessment should be performed to stratify patients into higher and lower risk categories and may assist in initial decisions such as timing of endoscopy, time of discharge, and level of care (Conditional recommendation). Discharge from the ED without inpatient endoscopy may be considered in patients with urea nitrogen < 18.2 mg / dl; Hgb 13.0 g / dl for men (12.0 g / dl for women), systolic blood pressure 110 mm Hg; pulse < 100 beats / min; and absence of melena, syncope, cardiac failure, and liver disease, as they have < 1 % chance of requiring intervention (Conditional recommendation). Laine & Jensen Am J Gastroenterol 2012; 107:345360 Slide 34 Management of Ulcer Bleeding: ACG Guidelines Pre-endoscopic interventions Intravenous infusion of erythromycin (250 mg ~ 30 min before endoscopy) should be considered to improve diagnostic yield and decrease the need for repeat endoscopy. However, erythromycin has not consistently been shown to improve clinical outcomes (Conditional recommendation). Pre-endoscopic intravenous PPI (e.g., 80 mg bolus followed by 8 mg / h infusion) may be considered to decrease the proportion of patients who have higher risk stigmata of hemorrhage at endoscopy and who receive endoscopic therapy. However, PPIs do not improve clinical outcomes such as further bleeding, surgery, or death (Conditional recommendation). If endoscopy will be delayed or cannot be performed, intravenous PPI is recommended to reduce further bleeding (Conditional recommendation). Nasogastric or orogastric lavage is not required in patients with UGIB for diagnosis, prognosis, visualization, or therapeutic effect (Conditional recommendation). Laine & Jensen Am J Gastroenterol 2012; 107:345360 Slide 35 Management of Ulcer Bleeding: ACG Guidelines Timing of endoscopy Patients with UGIB should generally undergo endoscopy within 24 h of admission, following resuscitative efforts to optimize hemodynamic parameters and other medical problems (Conditional recommendation). In patients who are hemodynamically stable and without serious comorbidities endoscopy should be performed as soon as possible in a non-emergent setting to identify the substantial proportion of patients with low-risk endoscopic findings who can be safely discharged (Conditional recommendation). In patients with higher risk clinical features (e.g., tachycardia, hypotension, bloody emesis or nasogastric aspirate in hospital) endoscopy within 12 h may be considered to potentially improve clinical outcomes (Conditional recommendation). Laine & Jensen Am J Gastroenterol 2012; 107:345360 Slide 36 Management of Ulcer Bleeding: ACG Guidelines - Endoscopy Stigmata of recent hemorrhage should be recorded as they predict risk of further bleeding and guide management decisions. The stigmata, in descending risk of further bleeding, are active spurting, non-bleeding visible vessel, active oozing, adherent clot, fl at pigmented spot, and clean base (Strong recommendation). Endoscopic therapy should be provided to patients with active spurting or oozing bleeding or a non-bleeding visible vessel (Strong recommendation). Endoscopic therapy may be considered for patients with an adherent clot resistant to vigorous irrigation. Benefi t may be greater in patients with clinical features potentially associated with a higher risk of rebleeding (e.g., older age, concurrent illness, inpatient at time bleeding began) (Conditional recommendation). Endoscopic therapy should not be provided to patients who have an ulcer with a clean base or a fl at pigmented spot (Strong recommendation). Laine & Jensen Am J Gastroenterol 2012; 107:345360 Slide 37 Management of Ulcer Bleeding: ACG Guidelines - Endoscopy Epinephrine therapy should not be used alone. If used, it should be combined with a second modality (Strong recommendation). Thermal therapy with bipolar electrocoagulation or heater probe and injection of sclerosant (e.g., absolute alcohol) are recommended because they reduce further bleeding, need for surgery, and mortality (Strong recommendation). Clips are recommended because they appear to decrease further bleeding and need for surgery. However, comparisons of clips vs. other therapies yield variable results and currently used clips have not been well studied (Conditional recommendation). For the subset of patients with actively bleeding ulcers, thermal therapy or epinephrine plus a second modality may be preferred over clips or sclerosant alone to achieve initial hemostasis (Conditional recommendation). Laine & Jensen Am J Gastroenterol 2012; 107:345360 Slide 38 Management of Ulcer Bleeding: ACG Guidelines - Therapy after initial endoscopy After successful endoscopic hemostasis, intravenous PPI therapy with 80 mg bolus followed by 8 mg/h continuous infusion for 72 h should be given to patients who have an ulcer with active bleeding, a non-bleeding visible vessel, or an adherent clot (Strong recommenda